

Rev04 DATASHEET

Update: Oct,19,2022

Anti-Durvalumab Antibody, pAb, Rabbit

Cat. No.: A02010

Overview

Specificity	The product is specific for Durvalumab.	
Host Species	Rabbit	
Immunogen	Durvalumab	
Conjugate	Unconjugated	

Applications

Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.

Application	Recommended Usage
ELISA	0.01-0.1 μg/ml

Properties

Form	Lyophilized	
Storage Buffer	Lyophilized with PBS, pH 7.4, containing 0.02% sodium azide.	
Reconstitution	Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.	
Storage Instructions	The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.	
Purification	Antigen affinity purification	
Isotype	Rabbit IgG	
Clonality	Polyclonal	

GenScript USA, Inc.




Note

GenScript can customize this product per customer's request including product size, buffer components, etc.

Examples

Anti-Durvalumab Antibody, pAb, Rabbit binds with Durvalumab



ELISA binding of Anti-Durvalumab Antibody (GenScript, A02010-40) with Durvalumab. While the antibody does not recognize the human IgG Fc fragment (data not shown). Coating antigen: Durvalumab, 1 μ g/ml. Anti-Durvalumab Antibody (GenScript, A02010-40) dilutions start from 1,000 ng/ml. EC₅₀= 7.301 ng/ml.

Background

Target Background: Durvalumab (Imfinzi) is a human IgG1κ monoclonal antibody that is approved by the U.S. Food and Drug Administration for the trea[™]ent of cancer. It was developed by Medimmune/AstraZeneca. Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody which blocks the interaction of PD-L1 with the PD-1 and CD80 molecules.GenScript Anti-Durvalumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Durvalumab.

Synonyms: Rabbit polyclonal antibody to Imfinzi

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.